Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery

Vaccine

Volumn 27, Issue 40, 2009, Pages 5450-5459

  Best, Simon R ^a   Peng, Shiwen ^a   Juang, Chi Mou ^b,c   Hung, Chien Fu ^a   Hannaman, Drew ^d   Saunders, John R ^a,e   Wu, T C ^a   Pai, Sara I ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Ichor Medical Systems Inc   (United States)

^e GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Calreticulin (CRT); DNA vaccine; Electroporation; Head and neck cancer; Human papillomavirus (HPV)

Indexed keywords

CALRETICULIN; DNA VACCINE; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTROPORATION; FEMALE; GENE GUN IMMUNIZATION; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ELECTROPORATION; FEMALE; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; VACCINES, DNA;

EID: 68349152636     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.005     Document Type: Article

References (59)

1. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20 (2002) 621-667
2. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
3. Pardoll D.M. Cancer vaccines. Nat Med 4 May (5 Suppl.) (1998) 525-531
4. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu Rev Immunol 15 (1997) 617-648
5. Robinson H.L. Nucleic acid vaccines: an overview. Vaccine 15 June (8) (1997) 785-787
6. Chaudhuri D., Suriano R., Mittelman A., and Tiwari R.K. Targeting the immune system in cancer. Curr Pharm Biotechnol 10 February (2) (2009) 166-184
7. Abdulhaqq S.A., and Weiner D.B. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42 1-3 (2008) 156-172
8. Braun S. Muscular gene transfer using nonviral vectors. Curr Gene Ther 8 October (5) (2008) 391-405
9. Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 11 November (Suppl. 2) (2007) S3-S9
10. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 May (19) (2007) 1944-1956
11. Kim J.W., Hung C.F., Juang J., He L., Kim T.W., Armstrong D.K., et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 11 June (12) (2004) 1011-1018
12. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60 February (4) (2000) 1035-1042
13. Hung C.F., Cheng W.F., Hsu K.F., Chai C.Y., He L., Ling M., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61 May (9) (2001) 3698-3703
14. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 82 July (13) (2008) 6458-6469
15. Sasaki S., Takeshita F., Xin K.Q., Ishii N., and Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31 November (3) (2003) 243-254
16. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101 September (37) (2004) 13601-13606
17. O'Hagan D.T., Singh M., and Ulmer J.B. Microparticles for the delivery of DNA vaccines. Immunol Rev 199 June (2004) 191-200
18. Mollenkopf H.J., Dietrich G., Fensterle J., Grode L., Diehl K.D., Knapp B., et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22 July (21/22) (2004) 2690-2695
19. Trimble C., Lin C.T., Hung C.F., Pai S., Juang J., He L., et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21 September (25/26) (2003) 4036-4042
20. Stoecklinger A., Grieshuber I., Scheiblhofer S., Weiss R., Ritter U., Kissenpfennig A., et al. Epidermal langerhans cells are dispensable for humoral and cell-mediated immunity elicited by gene gun immunization. J Immunol 179 July (2) (2007) 886-893
21. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., and Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188 September (6) (1998) 1075-1082
22. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96 April (8) (1999) 4262-4267
23. Aihara H., and Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16 September (9) (1998) 867-870
24. Peng B., Zhao Y., Xu L., and Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 25 March (11) (2007) 2064-2073
25. Study of a potential preventive vaccine against HIV in healthy volunteers (ADVAX-EP). NCT00545987; 2007. Available at: http://www.clinicaltrials.gov.
26. Phase I of human papillomavirus (HPV) DNA plasmid (VGX-3100) + electroporation for CIN 2 or 3. NCT00685412; 2008. Available at: http://www.clinicaltrials.gov.
27. Bloquel C., Trollet C., Pradines E., Seguin J., Scherman D., and Bureau M.F. Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee. BMC Biotechnol March (6) (2006) 16
28. Pike S.E., Yao L., Jones K.D., Cherney B., Appella E., Sakaguchi K., et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188 December (12) (1998) 2349-2356
29. Pike S.E., Yao L., Setsuda J., Jones K.D., Cherney B., Appella E., et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94 October (7) (1999) 2461-2468
30. Gronevik E., von Steyern F.V., Kalhovde J.M., Tjelle T.E., and Mathiesen I. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med 7 February (2) (2005) 218-227
31. Williams R.S., Johnston S.A., Riedy M., DeVit M.J., McElligott S.G., and Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci USA 88 (1991) 2726-2730
32. http://www.biocompare.com/Articles/TechnicalArticle/1198/Detection-Of-Reporter-Gene-Activity-In-Cell-Cultures-And-Murine-Epidermis-After-Helios-Gene-Gun-Mediated-Particle-Bombardment.html
33. Peng S., Trimble C., Alvarez R.D., Huh W.K., Lin Z., Monie A., et al. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8(+) T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 15 16 (2008) 1156-1166
34. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., and Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24 May (21) (2006) 4475-4481
35. Jones S., Evans K., McElwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27 April (18) (2009) 2506-2512
36. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 7-8 (2000) 764-778
37. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 6 (2003) 729-735
38. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197 June (12) (2008) 1634-1642
39. Martin J.E., Louder M.K., Holman L.A., Gordon I.J., Enama M.E., Larkin B.D., et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26 November (50) (2008) 6338-6343
40. Keitel W.A., Treanor J.J., El Sahly H.M., Evans T.G., Kopper S., Whitlow V., et al. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin 5. August (8) (2009)
41. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196 December (12) (2007) 1732-1740
42. Luxembourg A., Evans C.F., and Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 7 November (11) (2007) 1647-1664
43. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108 September (5) (2001) 669-678
44. Wang S., Zhang C., Zhang L., Li J., Huang Z., and Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26 April (17) (2008) 2100-2110
45. Saha S., Takeshita F., Sasaki S., Matsuda T., Tanaka T., Tozuka M., et al. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 24 September (37-39) (2006) 6240-6249
46. Rosati M., Valentin A., Jalah R., Patel V., von Gegerfelt A., Bergamaschi C., et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26 40 (2008) 5223-5229
47. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 May (9) (2000) 4635-4640
48. Ahlen G., Soderholm J., Tjelle T., Kjeken R., Frelin L., Hoglund U., et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179 October (7) (2007) 4741-4753
49. LeBlanc R., Vasquez Y., Hannaman D., and Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 26 January (2) (2008) 185-192
50. Luxembourg A., Hannaman D., Nolan E., Ellefsen B., Nakamura G., Chau L., et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 26 40 (2008) 5216-5222
51. Smorlesi A., Papalini F., Amici A., Orlando F., Pierpaoli S., Mancini C., et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24 March (11) (2006) 1766-1775
52. Cipriani B., Fridman A., Bendtsen C., Dharmapuri S., Mennuni C., Pak I., et al. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 19 7 (2008) 670-680
53. Roos A.K., Moreno S., Leder C., Pavlenko M., King A., and Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 13 February (2) (2006) 320-327
54. Lucas M.L., Heller L., Coppola D., and Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16, F10 melanoma. Mol Ther 5 June (6) (2002) 668-675
55. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
56. Jurk M., and Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 21 6 (2007) 387-401
57. Luxembourg A., Hannaman D., Ellefsen B., Nakamura G., and Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24 May (21) (2006) 4490-4493
58. Wu T.C., Guarnieri F.G., Staveley-O'Carroll K.F., Viscidi R.P., Levitsky H.I., Hedrick L., et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92 December (25) (1995) 11671-11675
59. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 January (1) (1996) 21-26